Alternative strategies in assuring blood safety: An overview
- PMID: 20110174
- DOI: 10.1016/j.biologicals.2009.10.009
Alternative strategies in assuring blood safety: An overview
Abstract
Assuring transfusion safety is an essential element of health care in all countries, requiring government commitment, national policy and a legal framework. Fundamental safety strategies include selection of low risk donors, Good Manufacturing Practices in preparation of blood components, and appropriate clinical use including avoidance of unnecessary transfusions. Hemovigilance, including surveillance for known adverse events and sentinel reporting of unexpected adverse events, enhances safety through benchmarking to promote best practices and by enabling rapid responses to new threats. Preventing transmission of infectious diseases is a principal safety concern. Selection of low risk donors includes use of screening questions to elicit risk factors known to be associated with transmissible infections. Laboratory testing for specific infectious disease markers is an established strategy for interdicting contaminated donations. The sensitivity, specificity, and operational convenience of laboratory testing have improved over time and newer technologies are imminent. Donor screening and laboratory testing, while highly effective in reducing risk, cannot eliminate all risk from known agents and must be developed de novo to address emerging infections. In contrast, pathogen reduction technologies offer the possibility for robust inactivation of a broad spectrum of blood transmissible agents and provide an added safeguard against newly emerging infectious threats of most types. Current pathogen reduction methods also inactivate leukocytes, adding safety benefits similar to leukocyte removal and product irradiation. However, to date, concerns about the safety and efficacy of cellular blood components treated by pathogen reduction have prevented approval of these technologies in the U.S. and Canada. FDA is promoting clinical and basic scientific studies to clarify these issues and would consider alternative approaches to assuring blood safety if pathogen reduction technologies are proven to be safe and effective.
Copyright 2009. Published by Elsevier Ltd.
Similar articles
-
Prevention of HIV transmission by blood transfusion in the developing world: achievements and continuing challenges.AIDS. 1998;12 Suppl A:S81-6. AIDS. 1998. PMID: 9632988 Review.
-
Pathogen-reduction systems for blood components: the current position and future trends.Transfus Apher Sci. 2006 Dec;35(3):189-96. doi: 10.1016/j.transci.2006.10.002. Epub 2006 Nov 15. Transfus Apher Sci. 2006. PMID: 17110168 Review.
-
How safe is blood, really?Biologicals. 2010 Jan;38(1):100-4. doi: 10.1016/j.biologicals.2009.10.008. Epub 2010 Jan 15. Biologicals. 2010. PMID: 20074975 Review.
-
Best practices in regulation of blood and blood products.Biologicals. 2012 May;40(3):200-4. doi: 10.1016/j.biologicals.2011.11.002. Epub 2011 Nov 27. Biologicals. 2012. PMID: 22122986
-
Update on pathogen reduction technology for therapeutic plasma: an overview.Transfus Apher Sci. 2006 Aug;35(1):83-90. doi: 10.1016/j.transci.2006.02.004. Epub 2006 Aug 24. Transfus Apher Sci. 2006. PMID: 16934528 Review.
Cited by
-
Alternative blood products and clinical needs in transfusion medicine.Stem Cells Int. 2012;2012:639561. doi: 10.1155/2012/639561. Epub 2012 Apr 8. Stem Cells Int. 2012. PMID: 22567025 Free PMC article.
-
Epidemiological Aspects of Hepatitis B and C Markers in Blood Donors in Kazakhstan; 2000-2011.Iran J Public Health. 2014 Feb;43(2):156-61. Iran J Public Health. 2014. PMID: 26060738 Free PMC article.
-
Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.Vox Sang. 2021 Jul;116(6):673-681. doi: 10.1111/vox.13043. Epub 2020 Dec 5. Vox Sang. 2021. PMID: 33277935 Free PMC article.
-
Latest Findings on the Effects of Gold Nanoparticles on the Storage Quality of Blood Products (2011-2022) - A Narrative Review.Curr Drug Deliv. 2025;22(5):537-551. doi: 10.2174/0115672018316266240909075316. Curr Drug Deliv. 2025. PMID: 39301911 Review.
-
Development of High Hydrostatic Pressure Applied in Pathogen Inactivation for Plasma.PLoS One. 2016 Aug 25;11(8):e0161775. doi: 10.1371/journal.pone.0161775. eCollection 2016. PLoS One. 2016. PMID: 27561010 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical